Amyotrophic Lateral Sclerosis (ALS) Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview: 

The amyotrophic lateral sclerosis market reached a value of USD 529.4 Million across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 779.8 Million by 2036, exhibiting a growth rate (CAGR) of 3.48% during 2026-2036.

The amyotrophic lateral sclerosis (ALS) market has been comprehensively analyzed in IMARC's new report titled "Amyotrophic Lateral Sclerosis (ALS) Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". The Amyotrophic Lateral Sclerosis (ALS) market is currently driven by factors such as a rising geriatric population, a strong drug pipeline that has a good efficacy and safety profile and improving diagnosis and drug treatment rates. Amyotrophic lateral sclerosis is a rare neurological disorder that predominantly affects the nerve cells (neurons) responsible for controlling voluntary muscle movement. Although the indication can happen at any age, symptoms most commonly appear between the ages of 55 and 75. With the geriatric population expected to increase significantly over the long term, we expect the incidence of Amyotrophic Lateral Sclerosis to increase significantly over the next few years.

ALS belongs to a broader group of disorders known as motor neuron diseases, which are caused due to the gradual deterioration (degeneration) and death of motor neurons. Motor neurons are nerve cells that extend throughout the body from the brain to the spinal cord and muscles. As motor neurons deteriorate, they cease sending messages to the muscles. As a result, the muscles gradually weaken, start to twitch, and waste away (atrophy). Eventually, this results in the brain losing its ability to initiate and control voluntary movements. Early symptoms of ALS normally include muscle weakness or stiffness. Gradually all voluntary muscles are affected, and patients lose their strength and the ability to speak, eat, move, and even breathe. The indication is progressive, resulting in the symptoms getting worse over time.

IMARC Group's new report provides an exhaustive analysis of the amyotrophic lateral sclerosis (ALS) market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for amyotrophic lateral sclerosis (ALS) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the amyotrophic lateral sclerosis (ALS) market in any manner.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, Current, and Future Epidemiology Scenario
• Historical, Current, and Future Performance of the Amyotrophic Lateral Sclerosis Market
• Historical, Current, and Future Performance of Various Therapeutic Categories in the Amyotrophic Lateral Sclerosis Market
• Sales of Various Drugs Across the Amyotrophic Lateral Sclerosis Market
• Reimbursement Scenario in the Amyotrophic Lateral Sclerosis Market

Competitive Landscape:

This report also provides a detailed analysis of the current Amyotrophic Lateral Sclerosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the amyotrophic lateral sclerosis (ALS) market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the amyotrophic lateral sclerosis (ALS) across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the amyotrophic lateral sclerosis (ALS) across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2020-2036) of amyotrophic lateral sclerosis (ALS) across the seven major markets?
• What is the number of prevalent cases (2020-2036) of amyotrophic lateral sclerosis (ALS) by age across the seven major markets?
• What is the number of prevalent cases (2020-2036) of amyotrophic lateral sclerosis (ALS) by gender across the seven major markets?
• What is the number of prevalent cases (2020-2036) of amyotrophic lateral sclerosis (ALS) by type across the seven major markets?
• How many patients are diagnosed (2020-2036) with amyotrophic lateral sclerosis (ALS) across the seven major markets?
• What is the size of the amyotrophic lateral sclerosis (ALS) patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend amyotrophic lateral sclerosis (ALS) of?
• What will be the growth rate of patients across the seven major markets?

Amyotrophic Lateral Sclerosis (ALS): Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for amyotrophic lateral sclerosis (ALS) drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the amyotrophic lateral sclerosis (ALS) market?
• What are the key regulatory events related to the amyotrophic lateral sclerosis (ALS) market?
• What is the structure of clinical trial landscape by status related to the amyotrophic lateral sclerosis (ALS) market?
• What is the structure of clinical trial landscape by phase related to the amyotrophic lateral sclerosis (ALS) market?
• What is the structure of clinical trial landscape by route of administration related to the amyotrophic lateral sclerosis (ALS) market?